To decide Recommended dose of XELIRI and bevacizumab in patients with metastatic colorectal cancer who have oxlplatin based first-line chemotherapy including treatment failure or refractory, and To evaluate the safety and efficacy -PhaseI/II Study
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2619389
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: XELIRI+ bevacizumab
Primary outcome(s): Phase I part: To decide Recommended dose Phase II part: Progression Free Survival
Study Design: Single arm Non-randomized
创建时间：
2010-07-15
